The momentum that biopharmaceutical companies gained in the eyes of investors in 2020 continued into 2021, delivering a record number of initial public offerings in the US for the second year in a row. However, biotechnology stock prices declined during the latter half of 2021, and by the end of December the average return for companies that went public in 2021 was -25.3%. Even so, experts expect a strong market for IPOs in 2022, but not enough offerings for a third record-breaking year.
IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted
Number Of 2021 Offerings Exceeded 2020, But Returns Faltered
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
More from Financing
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.